伊布利特治疗心房颤动和心房扑动的临床研究

CLINICAL STUDY OF IBUTILIDE ON TREATMENT OF ATRIALFIBRILLATION AND ATRIAL FLUTTER

目的:观察比较新型Ⅲ类抗心律失常药物伊布利特与普罗帕酮转复心房颤动和心房扑动的疗效。方法:按照制定的入选标准及排除标准选择受试者,采用随机、单盲对照进行观察。36例房颤/房扑患者,随机分入2组,伊布利特组(n=19)、普罗帕酮组(n=17)。依布利特1mg,于10min内静注;普罗帕酮70mg,于10min内静注。然后观察10min,若房扑/房颤仍未终止且QTc间期<550ms,分别给予第二剂,剂量相同。结果:观察房扑/房颤转复所用时间(从第一剂开始注射时算起)(min);观察房扑/房颤于用药后0～90min、90min～4h两组转复情况、转复时间的比较。通过对比分析,两组在2个时间段内转复情况及转复时间差异有统计学意义(P<0.01)。结论:伊布利特是使房扑、房颤快速转律的最有效药物,尤其是在用药后0～90min的时段内心房颤动和心房扑动的转复疗效更佳,明显优于普罗帕酮。

Objective ： To compare the of new Class Ⅲ antiarrhythmic drug ibutilide and propafenone in the conversion of atrial fibrillation and atrial flutter effect. Methods： In accordance with the eligibility criteria and eliminative critreria, randomized, single - blind controlled observation ,36 cases of atrial fibrillation / atrial flutter patients were randomly divided into two groups, ibutilide group （n = 19）. propafenone group （n = 17）. Ibutilide l mg within one injection pump; Propafenone administrated at one time injection pump within. 10 min and then observed for ten mimutes If atrial flutter / atrial fibrillation terminated yet also QTc 〈 550ms. Second dose were given. Results： Conversion of atrial flutter / atrial fibrillation used （from the first injection） （min） ; Observation of atrial flutter/atrial fibrillation in the treatment group after conversion in 0 - 90 min,90 min-4h time of conversion. By contrast the conversion of the two groups in two periods and the difference was statistically significant conversion （ P 〈 0.01 ）. Conclusion ：Ibutilide is atrial flutter/atrial fibrillation, rapid switch to the most effective drug. Particularly 0 ~ 90 min after administration in the period of conversion of atrial fibrillation and atrial flutter better efficacy, better than propafenone.